William W Hauswirth

William W Hauswirth

Eminent Scholar

Department: MD-OPHTHALMOLOGY
Business Phone: (352) 359-4301
Business Email: hauswrth@eye.ufl.edu

Publications

2020 Molecular Therapy : The Journal Of The American Society Of Gene Therapy
2019 Proceedings of the National Academy of Sciences of the United States of America. Biological Sciences
2018 Proceedings of the National Academy of Sciences of the United States of America. Biological Sciences
2018 Molecular Therapy : The Journal Of The American Society Of Gene Therapy
2016 Advances in Experimental Medicine and Biology
2016 Investigative Ophthalmology & Visual Science
2015 Proceedings of the National Academy of Sciences of the United States of America
2014 Proceedings of the National Academy of Sciences of the United States of America. Biological Sciences
2014 Investigative Ophthalmology & Visual Science
2013 Proceedings of the National Academy of Sciences of the United States of America
2013 Proceedings of the National Academy of Sciences of the United States of America
2013 Proceedings of the National Academy of Sciences of the United States of America
2012 Investigative Ophthalmology & Visual Science
2012 Journal of Comparative Neurology
2012 Proceedings of the National Academy of Sciences of the United States of America
2012 Proceedings of the National Academy of Sciences of the United States of America
2011 Proceedings of the National Academy of Sciences of the United States of America
2011 Proceedings of the National Academy of Sciences of the United States of America
2010 Investigative Ophthalmology & Visual Science
2010 Proceedings of the National Academy of Sciences of the United States of America
2009 Investigative Ophthalmology & Visual Science
2009 Investigative Ophthalmology & Visual Science
2009 Proceedings of the National Academy of Sciences of the United States of America
2008 Advances in Experimental Medicine and Biology
2008 Proceedings of the National Academy of Sciences of the United States of America
2008 Drug News & Perspectives
2008 Advances in Experimental Medicine and Biology
2005 Retina-the Journal of Retinal and Vitreous Diseases
2000 Investigative Ophthalmology & Visual Science
2000 Clinical Chemistry and Laboratory Medicine

Grants

September 2019 ACTIVE
Disease mechanisms of cone opsin mutants and treatment strategies
NATL INST OF HLTH NEI ·
March 2019 ACTIVE
Mito-Targeted AAV to Treat Leber Hereditary Optic Neuropathy Caused by ND4 Mutations
UNIV OF MIAMI · Principal Investigator
January 2019 – December 2019
Dual Vectors for Otoferlin
DECIBEL THERAPEUTICS · Principal Investigator
June 2018 – June 2019
Gene Therapy for RHO adRP
IVERIC BIO · Project Manager
April 2018 ACTIVE
Translational Gene Therapy for CNGB1 Retinitis Pigmentosa
MICHIGAN STATE UNIV · Principal Investigator
October 2017 – March 2019
Toxicology Study of BS01 in Rd1 mice
APPLIED GENETICS TECH CORP · Project Manager
September 2016 ACTIVE
CLARIN 1 RETINAL FUNCTION AND THERAPEUTIC IMPLICATIONS FOR USH3
NATL INST OF HLTH NEI ·
September 2016 ACTIVE
Translational Research for Retinal Degenerative Therapies
UNIV OF PENNSYLVANIA · Principal Investigator
August 2016 ACTIVE
Testing Gene Therapy in Models of Geographic Atrophy
NATL INST OF HLTH NEI ·
July 2016 – October 2017
XLRP Mouse Toxicology Study
APPLIED GENETICS TECH CORP ·
January 2016 – February 2018
AAV-Mediated Therapy for Best Vitelliform Macular Dystrophy
UNIV OF PENNSYLVANIA · Principal Investigator
October 2015 – October 2016
DSR Match Support – Gene Therapy for ABCA4 Stargar
UF DIV OF SPONSORED RES MATCHING FUNDS · Principal Investigator
September 2015 – September 2018
blue cone monochromancy
APPLIED GENETICS TECH CORP · Principal Investigator
September 2015 – August 2016
Translational Research for Retinal Degenerative Therapie
UNIV OF PENNSYLVANIA · Principal Investigator
May 2015 ACTIVE
Gene Therapy for ABCA4 Stargardt’s Disease
APPLIED GENETICS TECH CORP · Principal Investigator
January 2015 – June 2018
Gene Therapy for Blue Cone Monochromacy
BCM Families Foundation · Principal Investigator
June 2013 – November 2019
rAAV-CNGB3 Gene Therapy for Achromatopsia: Translational Research Studies
NATL INST OF HLTH NEI · Principal Investigator
February 2013 – January 2018
Population Coding in the Retina
CORNELL UNIV · Principal Investigator
January 2013 ACTIVE
Vitreal delivery of novel AAV vectors for blue cone mono
UF FOU · Principal Investigator
November 2012 – December 2016
XIAP gene therapy for the treatment of retinal degenerat
OTTAWA HOSP RESEARCH INST · Principal Investigator
October 2012 – September 2016
Gene therapy using novel cone-targeted adeno-associated
US ISRAEL BINATIONAL SCI FOU · Principal Investigator
August 2012 – July 2018
Gene Therapy for CEP290 LCA and RPE Dystrophies
FOU FOR FIGHTING BLINDNESS · Principal Investigator
March 2012 – February 2018
Translational Gene Therapy for Rhodopsin Autosomal Dominant Retinitis Pigmentosa (Module 1)
UNIV OF PENNSYLVANIA · Principal Investigator
October 2011 – June 2016
Gene Therapy for LCA1
FOU FOR FIGHTING BLINDNESS · Principal Investigator
August 2011 – July 2016
Vision Research Core
NATL INST OF HLTH NEI · Principal Investigator
July 2011 – June 2016
Module 1: Cone Targeted Gene Therapy
FOU FOR FIGHTING BLINDNESS · Principal Investigator
January 2011 ACTIVE
Purified Recombinant Adeno Associated Virus
MULTIPLE SPONSORS · Principal Investigator
January 2004 – May 2017
GENE THERAPY FOR RETINAL AND CHOROIDAL NEOVASCULAR DISEA
MACULAR VISION RESEARCH FOU · Principal Investigator

Patents

Issued November 2017
rAAV-Guanylate Cyclase Compositions and Methods for Treating Leber’s Congenital Amaurosis-1 (LCA1)
#9,816,108
Published October 2017
rAAV-Guanylate Cyclase Compositions and Methods for Treating Leber’s Congenital Amaurosis-1 (LCA1) (CON)
#US-2018-0100165
Issued September 2017
AAV-Mediated Gene Therapy for RPGR X-Linked Retinal Degeneration
#9,770,491
Published February 2017
AAV-Mediated Gene Therapy for NPHP5
#US17/0348387
Published October 2016
Method of Treating or Retarding the Development of Blindness (CON)
#US2017/0014529
Issued September 2016
Method of Treating or Retarding the Development of Blindness (CON)
#9,433,688
Published August 2016
Capsid-Mutated rAAV Vectors and Methods of Use (CON of 15258)
#US2016/0361439
Issued June 2016
Chimeric Promoter for Cone Photoreceptor Targeted Gene Therapy
#9,375,491
Published May 2016
Method of Treating or Retarding the Development of Blindness (CON)
#US-2016-026346-A1
Published March 2016
Methods and Compositions for Restoration of Cone Function in BCM
#US18/0112231
Published February 2016
rAAV Vector Compositions, Methods for Targeting Vascular Endothelial Cells and Use in Treatment of Type I Diabetes
#us2018/0057840
Issued December 2015
Reagents and Methods for Modulating Cone Photoreceptor Activity
#9,198,595
Published August 2015
Reagents and Methods for Modulating Cone Photoreceptor Activity (CON)
#US2016/0015288
Published February 2015
Methods and Compositions for Gene Delivery to On Bipolar Cells
#US2017/0007720
Published June 2014
Vectors for Delivery of Light Sensitive Proteins and Methods of Use (CON of 13128)
#US 2015/0225741
Published May 2014
Dual-AAV Vector-Based Systems and Methods for Delivering Oversized Genes to Mammalian Cells
#US2014/0256802
Published February 2013
Method of Treating or Retarding the Development of Blindness (CON)
#US-2013-0216500-A1
Issued October 2012
A Self-Complementary Adeno-Associated Virus Having a Truncated CMV-Chicken B-Actin Promoter
#8,298,818
Issued April 2012
Gene Therapy for Leber’s Congenital Amaurosis (LCA) and Other Early Onset Blinding Diseases (CON)
#8,147,823
Published March 2012
Reagents and Methods for Modulating Cone Photoreceptor Activity
#20120172419-A1
Published February 2012
Method of Treating or Retarding the Development of Blindness (CON)
#US-2012-0225930-A1
Published November 2010
Adeno-Associated Viral Vectors for Deliver of Light Sensitive Elements to Cells and Methods of Use
#US2012/0093772 A1
Published May 2010
Small Peptide Expression System in Mammalian Cells
#US-2012-0157513-A1
Published October 2008
Method of Treating or Retarding the Development of Blindess (CON)
#US-2009-0074723-A1
Issued March 2008
AAV-Delivered Ribozymes Compositions and Methods of Use
#7,342,111
Published August 2006
Method of Treating or Retarding the Development of Blindness
#US-2007-0077228-A1
Issued August 2006
Production of Pseudotyped Recombinant AAV Virions
#7,094,604
Published June 2005
Electroporation Device and Method for Delivery to Ocular Tissue
#US-2005-0277868-A1
Published September 2004
rAAV-Vector Compositions and Methods for the Treatment of Choroidal Neovascularization
#US-2006-0193830 A1
Published June 2003
Production of Pseudotyped Recombinant AAV Virions
#2007-0015238-A1
Published December 2002
Expression of Glial-Derived Neurotrophic Factor for Treatment of Diseases of the Eye
#US-2003-0129164-A1
Published November 2002
Method of Treating or Retarding the Development of Blindness
#US-2004-0022766A1
Issued May 2001
Rod Opsin mRNA-Specific Ribozyme Compositions and Methods for the Treatment of Retinal Diseases
#6,225,291
Issued February 2000
Humanized Green Fluorescent Protein Genes and Methods
#6,020,192
Issued October 1999
Humanized Green Fluorescent Protein Genes and Methods
#5,968,750
Issued February 1999
Humanized Green Fluorescent Protein Genes And Methods
#5,874,304

Contact Details

Phones:
Business:
(352) 359-4301
Emails: